Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Dr. Lian-Wang Guo | Genetics and Molecular Biology| Best Researcher Award

Professor at University of Virginia, United States

Dr. Lian-Wang Guo is a Professor of Biomedical Sciences at the University of Virginia with over 20 years of experience in vascular biology and biochemistry. His research primarily focuses on the role of epigenetic modulators in vascular diseases, particularly neointima-associated restenosis. He has been continuously funded by the NIH since 2012 and has published 48 peer-reviewed papers in the past six years, while also filing six patent applications. Dr. Guo’s innovative work includes developing biomimetic nanoplatforms for targeted drug delivery, which are currently in advanced trials for treating vascular conditions. His research integrates basic science with clinical applications, notably through collaboration with Dr. Craig Kent. Dr. Guo is recognized for his significant contributions to vascular epigenetics and has created a rigorous and inclusive training environment for young researchers. His work holds promise for advancing therapeutic strategies and improving clinical outcomes for vascular diseases.

Professional Profile

Education

Dr. Lian-Wang Guo’s educational background is rooted in biology and advanced plant physiology, providing a strong foundation for his extensive research career. He earned his Bachelor of Science degree in Biology from Xinjiang University in China in 1989, followed by a Master of Science in Plant Physiology from the prestigious Chinese Academy of Sciences in 1992. He continued his studies there, earning a Ph.D. in Plant Physiology and Biochemistry in 1995. Driven by a passion for genetics and biochemistry, Dr. Guo completed a postdoctoral fellowship at The Hebrew University of Jerusalem in 1998, where he broadened his research expertise in molecular biology. His educational journey reflects a commitment to understanding complex biological processes, which he has successfully applied to his pioneering work in vascular biology and epigenetics. Dr. Guo’s solid academic training has been instrumental in his innovative research contributions and leadership in biomedical sciences.

Professional Experience

Dr. Lian-Wang Guo is a tenured Professor of Biomedical Sciences at the University of Virginia, specializing in vascular biology and epigenetics. With over 20 years of research experience, Dr. Guo has developed an expertise in chromatin modulators and their role in vascular diseases, particularly in neointima-associated restenosis. He has been continuously funded by the NIH since 2012, and his prolific contributions include 48 peer-reviewed publications and multiple patents, reflecting his leadership in vascular epigenetics research. His laboratory employs advanced molecular techniques such as ChIPseq, RNAseq, bioinformatics, and innovative nanoplatforms for targeted drug delivery. Dr. Guo has also successfully fostered clinical collaborations, including the development of therapeutic interventions currently undergoing large animal trials, with preparations for human studies. A dedicated mentor, he has cultivated a rigorous training environment for students and fellows, helping them transition into independent research careers. His research has garnered numerous awards and recognition from prominent scientific organizations.

Research Interests

Lian-Wang Guo’s research interests center around the intersection of vascular biology, epigenetics, and targeted drug delivery. As a professor of Biomedical Sciences, his work focuses on understanding the role of chromatin modulators, such as EZH2, DOT1L, and BRD4, in vascular diseases, particularly neointima-associated restenosis. By uncovering how these epigenetic regulators influence disease-specific gene expression, he aims to develop precise therapeutic strategies that mitigate pathological vascular remodeling while preserving normal cellular functions. Dr. Guo is also deeply involved in translational research, advancing the use of biomimetic nanoplatforms for targeted, localized drug delivery. His lab has developed innovative nanotechnologies to deliver therapeutic agents to disease sites, aiming to enhance efficacy and minimize side effects. A key element of his research is the integration of basic science discoveries with clinical applications, as evidenced by his collaborations on vascular disease treatments currently in advanced stages of preclinical testing.

Lian-Wang Guo, Professor of Biomedical Sciences at the University of Virginia, has earned numerous prestigious awards and honors throughout his distinguished career. In 1996, he received the Award of Excellent Sci/Tech Articles from the Chinese Society of Plant Physiology. He has also been recognized with the University of Wisconsin-Madison Eye Research Institute Rapid Response Initiative Award (2008), the Morgridge Institute for Research Award (2014), and the New Investigator Award from the State of Wisconsin Partnership Program (2014). At The Ohio State University, he earned the Accelerator Award for Translation (2017). His editorial contributions include serving as Lead Guest Editor for Genes and Associate Editor for Frontiers in Cardiovascular Medicine. In 2023, he was elected as a Fellow of the American Heart Association (FAHA), and his outstanding research earned him recognition at the 2023 Research Achievement event at the University of Virginia, marking him as a leading figure in vascular biology and biomedical research.

Dr. Lian-Wang Guo’s extensive research contributions, particularly in vascular biology and epigenetics, position him as a leading scholar in biomedical sciences. His innovative work on chromatin modulators, specifically targeting epigenetic players like BRD4, EZH2, and DOT1L, has brought new insights into the treatment of neointimal-associated vascular diseases. Additionally, his development of nano-based, targeted drug delivery systems has shown promising translational potential, bridging the gap between basic science and clinical applications. With over 20 years of experience, numerous high-impact publications, NIH funding, and significant patents, Dr. Guo’s work is both cutting-edge and impactful. His mentorship of the next generation of scientists, as well as his collaborations with leading clinicians, further enhance his academic profile. While his contributions are already significant, a continued focus on clinical translation could maximize the impact of his research. Overall, Dr. Guo exemplifies the qualities of an outstanding researcher deserving of recognition.

 

Publication top noted
  • Article: Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression
    Authors: Li, J., Shen, H., Guo, L.-W.
    Year: 2024
    Citations: 0
  • Article: miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4
    Authors: Xie, X., Shirasu, T., Li, J., Guo, L.-W., Kent, K.C.
    Year: 2023
    Citations: 3
  • Article: Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
    Authors: Shirasu, T., Yodsanit, N., Li, J., Gong, S., Guo, L.-W.
    Year: 2023
    Citations: 1
  • Article: Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms
    Authors: Yodsanit, N., Shirasu, T., Huang, Y., Gong, S., Wang, B.
    Year: 2023
    Citations: 2
  • Article: Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
    Authors: Zhang, M., Li, J., Wang, Q., Miller, C.L., Guo, L.-W.
    Year: 2023
    Citations: 3
  • Article: Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists
    Authors: Li, J., Satyshur, K.A., Guo, L.-W., Ruoho, A.E.
    Year: 2023
    Citations: 3
  • Article: Retinal Photoreceptor Protection in an AMD-Related Mouse Model by Selective Sigma-1 or Sigma-2 Receptor Modulation
    Authors: Mavlyutov, T.A., Li, J., Liu, X., Pattnaik, B., Guo, L.-W.
    Year: 2022
    Citations: 4
  • Erratum: Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction (Cell Death Discovery, (2021), 7, 1, (318), 10.1038/s41420-021-00720-9)
    Authors: Xie, X., Guo, L.-W., Kent, C.K.
    Year: 2022
    Citations: 0
  • Article: Differential Responses to Sigma-1 or Sigma-2 Receptor Ablation in Adiposity, Fat Oxidation, and Sexual Dimorphism
    Authors: Li, J., Félix-Soriano, E., Wright, K.R., Stanford, K.I., Guo, L.-W.
    Year: 2022
    Citations: 5
  • Article: SREBP1 regulates Lgals3 activation in response to cholesterol loading
    Authors: Li, J., Shen, H., Owens, G.K., Guo, L.-W.
    Year: 2022
    Citations: 9

Paul Cullen | Genetics | Best Researcher Award

Dr. Paul Cullen | Genetics | Best Researcher Award

Doctorate at University at Buffalo, United States

Dr. Paul Cullen is a Professor in the Department of Biological Sciences at the University at Buffalo, specializing in molecular genetics and cell biology. He completed his postdoctoral training at the Institute of Molecular Biology at the University of Oregon, where he worked on MAP kinase (MAPK) signaling pathways, funded by grants from the American Heart Association and the National Institutes of Health (NIH). Dr. Cullen earned his Ph.D. in Molecular Genetics from Washington University in Saint Louis, where his research focused on bacterial nitrogen control proteins. He holds a Bachelor of Science in Biological Sciences from the University of Illinois at Urbana-Champaign, graduating Magna Cum Laude with Distinction. Dr. Cullen’s research interests revolve around understanding the regulation of cellular differentiation and signaling pathways, particularly in yeast. He has received numerous accolades, including the UB Exceptional Scholar’s Award and the Distinguished Postdoc Mentor Award. His work is supported by multiple NIH grants, and he has contributed significantly to the scientific community through publications and mentorship.

Education

Dr. Paul Cullen holds an impressive educational background in the field of biological sciences and molecular genetics. He earned his Bachelor of Science degree in Biological Sciences from the University of Illinois, Urbana-Champaign, graduating Magna Cum Laude with Distinction in 1990. His undergraduate thesis, titled “Effect of Ecdysone on In Vitro Pupal Wing Development in Lepidoptera,” was conducted under the supervision of Dr. Judith Willis and Dr. Johnathan Widom. Following this, Dr. Cullen pursued his Doctor of Philosophy (Ph.D.) in Molecular Genetics at Washington University, Saint Louis, completing his degree in 1997. His Ph.D. research, titled “Bacterial Nitrogen Control Proteins,” was guided by Dr. Robert G. Kranz. Additionally, from 1998 to 2004, Dr. Cullen completed postdoctoral training at the Institute of Molecular Biology at the University of Oregon, under the mentorship of Dr. George F. Sprague, Jr. His postdoctoral work was supported by prestigious grants from the American Heart Association and the National Institutes of Health (NIH), further solidifying his expertise in molecular biology.

Professional Experience

Dr. Paul Cullen has held a series of prestigious academic and research positions throughout his career. He is currently a Professor in the Department of Biological Sciences at the University at Buffalo, where he has been a faculty member since 2004. Prior to his promotion to Professor in 2017, Dr. Cullen served as an Associate Professor from 2010 to 2017 and as an Assistant Professor from 2004 to 2010. He has also held a joint appointment as Clinical Research Assistant Professor in the Department of Microbiology and Immunology since 2005. Earlier in his career, Dr. Cullen was a Senior Research Fellow at the Institute of Molecular Biology at the University of Oregon from 2000 to 2004. He has also contributed to scientific review panels, including serving as an NIH Review Panelist for Eukaryotic Pathogens in 2024. In addition to his research, Dr. Cullen has been deeply involved in academic administration, serving as the Director of Graduate Affairs for the Department of Biological Sciences from 2019 to 2024 and as a member of the Graduate School Executive Committee from 2023 to 2024.

Research Interest

Dr. Paul Cullen’s research interests focus on understanding the molecular mechanisms that regulate cellular differentiation, particularly through MAP kinase (MAPK) signaling pathways. His work explores how these pathways control cellular responses to environmental cues, with a special emphasis on the filamentous growth of Saccharomyces cerevisiae (yeast). Dr. Cullen investigates the role of cell polarity proteins in modulating MAPK signaling and how regulatory proteins influence these pathways. His research also extends to studying signal transduction in various biological systems, aiming to uncover broader implications for cellular behavior and development in eukaryotic organisms. Through his work, Dr. Cullen seeks to advance knowledge of genetic and molecular processes that underpin complex biological responses, contributing to the fields of molecular genetics, cell biology, and microbiology.

Research Skills

Dr. Paul Cullen possesses extensive research skills in molecular genetics and cell biology, particularly in the regulation of MAP kinase (MAPK) signaling pathways. His expertise includes advanced molecular techniques such as gene manipulation, protein-protein interaction studies, and genetic screening in model organisms like Saccharomyces cerevisiae. Dr. Cullen is skilled in using molecular and genetic tools to investigate cellular differentiation, signal transduction, and environmental response mechanisms. He has a strong background in high-throughput screening, microscopy, and quantitative data analysis. His research also involves cutting-edge technologies in genetic sequencing, bioinformatics, and structural biology, contributing to his deep understanding of cellular signaling networks and their implications for health and disease.

Award and Recognition

Dr. Paul Cullen has received numerous accolades for his exemplary contributions to research and education. In 2023, he was honored with the UB Exceptional Scholar’s Award for Sustained Achievement and the UB Graduate School Distinguished Postdoc Mentor Award, recognizing his significant impact in mentorship. Additionally, he received the Milton Plesur Excellence in Teaching Award in 2008 for his dedication to student learning. His active membership in professional organizations such as the American Society of Cell Biology and the American Society of Microbiology further highlights his commitment to advancing the field of molecular biology.

Conclusion

Dr. Paul Cullen’s remarkable achievements in molecular biology, sustained research contributions, and commitment to mentoring make him a distinguished figure in his field. His combination of academic excellence, leadership, and impactful research positions him as an exemplary candidate for the “Research for Best Researcher Award.”

Publication Top Notes

  • “Glucose depletion causes haploid invasive growth in yeast”
    • Journal: Proceedings of the National Academy of Sciences
    • Cited by: 444
    • Year: 2000
    • Volume: 97, Issue 25
    • Pages: 13619-13624
  • “The regulation of filamentous growth in yeast”
    • Journal: Genetics
    • Cited by: 348
    • Year: 2012
    • Volume: 190, Issue 1
    • Pages: 23-49
  • “A signaling mucin at the head of the Cdc42-and MAPK-dependent filamentous growth pathway in yeast”
    • Journal: Genes & Development
    • Cited by: 268
    • Year: 2004
    • Volume: 18, Issue 14
    • Pages: 1695-1708
  • “GTPase-activating proteins for Cdc42”
    • Journal: Eukaryotic Cell
    • Cited by: 170
    • Year: 2002
    • Volume: 1, Issue 3
    • Pages: 469-480
  • “Defects in Protein Glycosylation Cause SHO1-Dependent Activation of a STE12 Signaling Pathway in Yeast”
    • Journal: Genetics
    • Cited by: 147
    • Year: 2000
    • Volume: 155, Issue 3
    • Pages: 1005-1018
  • “Cleavage of the signaling mucin Msb2 by the aspartyl protease Yps1 is required for MAPK activation in yeast”
    • Journal: The Journal of Cell Biology
    • Cited by: 144
    • Year: 2008
    • Volume: 181, Issue 7
    • Pages: 1073-1081
  • “Secreted aspartic protease cleavage of Candida albicans Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis”
    • Journal: PLoS One
    • Cited by: 112
    • Year: 2012
    • Volume: 7, Issue 11
    • Pages: e46020
  • “Candida albicans biofilm development is governed by cooperative attachment and adhesion maintenance proteins”
    • Journal: NPJ Biofilms and Microbiomes
    • Cited by: 111
    • Year: 2019
    • Volume: 5, Issue 1
    • Pages: 21